Published in Anal Bioanal Chem on July 08, 2008
Recent developments in sweat analysis and its applications. Int J Anal Chem (2015) 0.87
Monitoring pregnant women's illicit opiate and cocaine use with sweat testing. Ther Drug Monit (2010) 0.79
Cellular phone-based image acquisition and quantitative ratiometric method for detecting cocaine and benzoylecgonine for biological and forensic applications. Subst Abuse (2010) 0.79
Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry. J Anal Toxicol (2009) 0.79
Simultaneous analysis of buprenorphine, methadone, cocaine, opiates and nicotine metabolites in sweat by liquid chromatography tandem mass spectrometry. Anal Bioanal Chem (2010) 0.78
Excretion of methadone in sweat of pregnant women throughout gestation after controlled methadone administration. Ther Drug Monit (2010) 0.78
Sweat testing for heroin, cocaine, and metabolites. J Anal Toxicol (1994) 1.86
Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for delta(9)-tetrahydrocannabinol in sweat patches. Clin Chem (2004) 1.66
An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug Alcohol Rev (2004) 1.47
Sweat testing in opioid users with a sweat patch. J Anal Toxicol (1996) 1.05
Disposition of cocaine and its metabolites in human sweat after controlled cocaine administration. Clin Chem (2005) 1.01
Excretion of Delta9-tetrahydrocannabinol in sweat. Forensic Sci Int (2007) 0.98
Opioid disposition in human sweat after controlled oral codeine administration. Clin Chem (2006) 0.97
The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma. J Pharm Pharmacol (1992) 0.96
Sweat testing for cocaine, codeine and metabolites by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl (1999) 0.95
Usefulness of sweat testing for the detection of MDMA after a single-dose administration. J Anal Toxicol (2003) 0.93
The use of oral fluid and sweat wipes for the detection of drugs of abuse in drivers. J Forensic Sci (2002) 0.90
Measurement of heroin and its metabolites by isotope-dilution electron-impact mass spectrometry. Clin Chem (1993) 0.90
Sweat testing for heroin and metabolites in a heroin maintenance program. Clin Chem (1997) 0.90
Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. Clin Chem (2007) 0.90
Enantioselective analysis of methadone in sweat as monitored by liquid chromatography/ion spray-mass spectrometry. Ther Drug Monit (1998) 0.89
Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers. J Anal Toxicol (2000) 0.89
Drug testing in addicts: a comparison between urine, sweat, and hair. Ther Drug Monit (1996) 0.89
Determination of methadone and its N-demethylation metabolites in biological specimens by GC-PICI-MS. J Anal Toxicol (1996) 0.87
Legal, workplace, and treatment drug testing with alternate biological matrices on a global scale. Forensic Sci Int (2001) 0.86
Detecting crack and other cocaine use with fastpatches. Addict Biol (2003) 0.85
Sweat testing in addicts under methadone treatment: an Italian experience. Forensic Sci Int (2007) 0.85
Acetylcodeine as a marker of illicit heroin abuse in oral fluid samples. J Anal Toxicol (2006) 0.85
Preliminary practical findings on drug monitoring by a transcutaneous collection device. J Forensic Sci (1996) 0.84
Automated solid-phase extraction and two-step derivatisation for simultaneous analysis of basic illicit drugs in serum by GC/MS. Int J Legal Med (2000) 0.82
Excretion of methadone and metabolites in human sweat. Res Commun Chem Pathol Pharmacol (1973) 0.82
Perspiration versus saliva--basic aspects concerning their use in roadside drug testing. Int J Legal Med (1999) 0.82
Detection of cocaine and cocaethylene in sweat by solid-phase microextraction and gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.81
Dosage regimes in the prescription of heroin and other narcotics to chronic opioid addicts in Switzerland--Swiss national cohort study. Eur Addict Res (2004) 0.81
Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.80
Comparative analysis of sweat patches for cocaine (and metabolites) by radioimmunoassay and gas chromatography-positive ion chemical ionization-mass spectrometry. J Anal Toxicol (2004) 0.78
Acetylcodeine as a urinary marker to differentiate the use of street heroin and pharmaceutical heroin. J Anal Toxicol (2002) 0.77
Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction (2011) 3.42
Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend (2003) 2.68
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend (2005) 2.26
Cannabis effects on driving skills. Clin Chem (2012) 2.04
Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict (2006) 1.94
Oral fluid testing for drugs of abuse. Clin Chem (2009) 1.89
Guidelines for research on drugged driving. Addiction (2008) 1.87
Methadone maintenance and breastfeeding in the neonatal period. Pediatrics (2008) 1.86
Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem (2013) 1.67
Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem (2003) 1.66
Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for delta(9)-tetrahydrocannabinol in sweat patches. Clin Chem (2004) 1.66
Acute nicotine differentially impacts anticipatory valence- and magnitude-related striatal activity. Biol Psychiatry (2012) 1.62
Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci (2007) 1.61
On-site test for cannabinoids in oral fluid. Clin Chem (2012) 1.57
Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chromatogr A (2010) 1.53
Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. Clin Chem (2003) 1.48
Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend (2009) 1.40
Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom (2003) 1.31
Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit (2008) 1.29
Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin Chem (2011) 1.29
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem (2013) 1.29
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem (2009) 1.28
Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend (2004) 1.26
Just say "I don't": lack of concordance between teen report and biological measures of drug use. Pediatrics (2010) 1.26
Cognitive measures in long-term cannabis users. J Clin Pharmacol (2002) 1.23
Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. Clin Chem (2002) 1.23
Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol (2010) 1.22
Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict (2006) 1.21
Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr (2010) 1.21
Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction (2009) 1.21
Prenatal and postnatal cocaine exposure predict teen cocaine use. Neurotoxicol Teratol (2010) 1.19
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem (2010) 1.19
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem (2011) 1.18
Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit (2004) 1.16
Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol (2009) 1.16
Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem (2014) 1.15
Oral fluid as a diagnostic tool. Clin Chem Lab Med (2004) 1.15
Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos (2009) 1.15
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend (2012) 1.14
Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact (2007) 1.12
Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol (2003) 1.11
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem (2010) 1.11
Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol (2007) 1.11
Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol (2008) 1.10
Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit (2009) 1.10
Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol (2009) 1.09
Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem (2012) 1.09
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit (2006) 1.07
A mechanism for the inhibition of neural progenitor cell proliferation by cocaine. PLoS Med (2008) 1.07
Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. Clin Chem (2009) 1.05
A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal Bioanal Chem (2009) 1.05
Metabolic effects of chronic cannabis smoking. Diabetes Care (2013) 1.04
A validated method for the determination of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J Mass Spectrom (2006) 1.04
Quantification of nicotine, cotinine, trans-3'-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.03
Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 1.03
Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Test Anal (2014) 1.03
Performance effects of nicotine during selective attention, divided attention, and simple stimulus detection: an fMRI study. Cereb Cortex (2008) 1.03
Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics (2012) 1.03
A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry (2013) 1.03
First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem (2013) 1.01
Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol (2008) 1.01
Disposition of cocaine and its metabolites in human sweat after controlled cocaine administration. Clin Chem (2005) 1.01
The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J (2006) 1.01
Nicotine and metabolites in meconium as evidence of maternal cigarette smoking during pregnancy and predictors of neonatal growth deficits. Nicotine Tob Res (2010) 1.01
Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem (2013) 1.01
Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. J Anal Toxicol (2006) 1.01
Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. Ther Drug Monit (2014) 1.00
Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci (2007) 1.00
Urinary elimination of cocaine metabolites in chronic cocaine users during cessation. J Anal Toxicol (2002) 1.00
Strategies for quitting among non-treatment-seeking marijuana smokers. Am J Addict (2005) 1.00
Relative performance of common biochemical indicators in detecting cigarette smoking. Addiction (2011) 0.99
THC can be detected in brain while absent in blood. J Anal Toxicol (2005) 0.99
Validation of Large White Pig as an animal model for the study of cannabinoids metabolism: application to the study of THC distribution in tissues. Forensic Sci Int (2006) 0.99
Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction (2010) 0.98
Validated method for the simultaneous determination of Delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.98
Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. Drug Alcohol Depend (2006) 0.98
Transcriptional changes common to human cocaine, cannabis and phencyclidine abuse. PLoS One (2006) 0.98
Simultaneous and sensitive measurement of nicotine, cotinine, trans-3'-hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.98